Multi-route Nasal Drug Delivery Technology
TrigeNas™
Revolutionizing how medicines reach the brain and body
A New Route
to Precision Medicine
Even the most advanced compounds often fail to cross the blood-brain barrier (BBB) — a lipid membrane that blocks 98% of small molecules and nearly all larger ones. For treatments targeting the brain or central nervous system (CNS), this remains one of modern medicine’s greatest challenges.
TrigeNas™ provides an elegant solution: a nasal delivery platform that uses the body’s own neurovascular architecture to deliver drugs directly and effectively — including to the brain.
Three Pathways. One Platform.
By targeting these routes simultaneously, TrigeNas™ enables both systemic and CNS-direct administration — without injections, without pain, and without compromising patient comfort.
1. Olfactory (Cranial Nerve I)
Aroma-controlled activation via the olfactory mucosa
Clinical Advantage: Direct and rapid nose-to-brain access
2. Trigeminal (Cranial Nerve V)
Mechano- and chemosensory activation in the nasal valve
Clinical Advantage: Enhanced absorption and neurostimulation
3. Vascular (Kiesselbach’s Plexus)
Ultra-vascularized area for systemic uptake
Clinical Advantage: Fast and efficient absorption into circulation
A Game-Changing Technology
TrigeNas™ is a proprietary polyurethane (PU) foam nasal plug designed for optimal comfort, retention, and drug release. The plug can be soaked, coated, or injected with active substances, including biologics, nano-gels, liposomes, or microspheres.
An umbrella-shaped valve ensures that active agents are gradually released during inhalation but retained during exhalation, preventing loss and maximizing bioavailability.
Unlike traditional sprays or powders that are cleared within minutes by the nasal mucociliary system, TrigeNas™ remains in place for hours, allowing steady and prolonged absorption.
The platform can be adapted to existing drugs, vaccines, and delivery vehicles — enabling pharma partners to enhance established formulations without the cost and risk of developing new molecular entities.
Clinical and Therapeutic Applications
The TrigeNas™ platform opens vast opportunities across multiple therapeutic domains:
Neurological disorders: Alzheimer’s, Parkinson’s, Epilepsy
Psychiatric conditions: Depression, Schizophrenia
Pain and migraine management
Hormone and peptide therapy
Biologic and nano-formulated drugs
Nasal and mucosal vaccination
By enabling precise and consistent dosing, TrigeNas™ minimizes systemic side effects while accelerating onset of action — ideal for both acute and chronic conditions requiring CNS access.
Why It Matters
With its unique ability to combine vascular, neural, and mechanical activation, TrigeNas™ represents a paradigm shift in drug delivery — from systemic injection to targeted nasal precision.
Needle-Free and Non-Invasive
Enhanced comfort and compliance
Rapid Onset, Controlled Duration
Optimized for both immediate and sustained delivery
Bypasses First-Pass Metabolism
Higher bioavailability with lower dose requirements
Patient-Independent Application
Simple, self-administered, and consistent results
Regulatory-Ready Design
Based on an already CE-approved device platform
Join the Revolution in Precision Medicine
Hogne AB is actively seeking pharmaceutical and biotechnology partners to co-develop, test, and commercialize TrigeNas™ applications for advanced therapeutics and vaccines.
With an established CE-marked base device (NosePlug®), proven market traction, and a strong IP position, Hogne offers a rapid pathway from concept to clinical reality.
Let’s shape the future of medicine — together.